Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,018 public trials 2,029 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

NCT03277105

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Levine Cancer Institute Charlotte, North Carolina, United States
  • Royal Prince Alfred Hospital Camperdown, Australia
  • St Vincents Hospital Melbourne Fitzroy, Australia
View all 146 locations
View Trial Details
Completed

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

NCT03412565

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Cancer Center of Central Connecticut - Southington Southington, Connecticut, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • UF Health Cancer Center at Orlando Health Orlando, Florida, United States
  • Karmonos Cancer Institute Detroit, Michigan, United States
View all 64 locations
View Trial Details
Completed

Safety and Efficacy of the CarboClear Pedicle Screw System

NCT02626624

Conditions
Bone Diseases, Degenerative Disc Disease, Hemic and Lymphatic Diseases, +16 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Mayo Clinic Rochester, Minnesota, United States
  • The Brooklyn Hospital Brooklyn, New York, United States
  • Crystal Clinic Orthopaedic Center Akron, Ohio, United States
View Trial Details
Completed

A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

NCT05347485

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • City of Hope Duarte, California, United States
  • University of California San Francisco San Francisco, California, United States
  • Stanford University Medical Center Stanford, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
View all 18 locations
View Trial Details
Completed

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

NCT01998971

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Duarte, California, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Indianapolis, Indiana, United States
View all 22 locations
View Trial Details
Completed

Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

NCT03939182

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
Locations
  • Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
  • Memorial Sloan Kettering Commack Commack, New York, United States
  • Memorial Sloan Kettering Westchester Harrison, New York, United States
View Trial Details
Completed

TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

NCT03860038

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Beijing Chao-Yang Hospital,Capital medical university Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital Beijing, Beijing Municipality, China
  • Fujian Medical University Union Hospital Fuzhou, Fujian, China
  • Nanfang Hospital of SMU Guangzhou, Guandong, China
View all 18 locations
View Trial Details

Related conditions